A note on FDA’s leadership transition

By now you've likely seen reports that Dr. Marty Makary has resigned as FDA Commissioner, with Kyle Diamantas stepping in as acting commissioner. What does that mean for compounding? We wanted to say something directly, even if what we can say right now is mostly: we don't know yet.

If you want the backstory on how it unfolded, the Wall Street Journal has a detailed account – the short version is that Makary lost the confidence of the White House and RFK Jr. over a range of issues, with flavored vaping policy serving as the final breaking point. Not exactly a compounding story, but context worth having.

It's genuinely too early to draw conclusions about what this transition means – for GLP-1 enforcement, compounding policy, peptides, or any of the other issues we've been tracking. Leadership transitions at FDA can signal shifts in priority and posture, or they can turn out to be largely administrative. We've seen both. APC is watching closely and will continue engaging with policymakers as things develop. In the meantime, steady as she goes.